These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 12722394)

  • 1. [Evaluation of the effectiveness of second-line intraperitoneal chemotherapy for patients with ovarian cancer].
    Milczek T; Emerich J; Debniak J; Klasa-Mazurkiewicz D
    Ginekol Pol; 2002 Nov; 73(11):1027-33. PubMed ID: 12722394
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Surgical complications connected with intraperitoneal chemotherapy in ovarian cancer].
    Milczek T; Emerich J; Klasa-Mazurkiewicz D
    Ginekol Pol; 2003 Sep; 74(9):817-23. PubMed ID: 14674130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Evaluation of surgical complications connected with intraperitoneal chemotherapy in ovarian cancer].
    Emerich J; Milczek T; Debniak J; Majdak E
    Ginekol Pol; 2002 Nov; 73(11):1103-8. PubMed ID: 12722406
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer.
    Piver MS; Recio FO; Baker TR; Driscoll D
    Cancer; 1994 Mar; 73(6):1693-8. PubMed ID: 7512437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
    Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
    Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of risk factors after intraperitoneal chemotherapy in patients with ovarian cancer].
    Milczek T; Emerich J; Debniak J; Liro M
    Ginekol Pol; 2001 Apr; 72(4):212-6. PubMed ID: 11444177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Five-year survival after second-line cisplatin-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Recio FO; Piver MS; Hempling RE; Driscoll DL
    Gynecol Oncol; 1998 Mar; 68(3):267-73. PubMed ID: 9570979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparative study of different chemotherapy approaches for advanced epithelial ovarian cancer].
    Chen YL; Liu YQ; Tang DH; Chu CN
    Zhonghua Fu Chan Ke Za Zhi; 2008 Feb; 43(2):110-4. PubMed ID: 18683749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous chemotherapy, early debulking surgery, and consolidation intraperitoneal chemotherapy in advanced ovarian carcinoma.
    Tournigand C; Louvet C; Molitor JL; Dehni N; Lejeune V; Sezeur A; Pigne A; Marpeau L; Cady J; de Gramont A
    Gynecol Oncol; 2001 Nov; 83(2):198-204. PubMed ID: 11606072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
    Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
    J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second line platinum-based intraperitoneal chemotherapy for advanced ovarian cancer.
    Milczek T; Klasa-Mazurkiewicz D; Emerich J; Kobierski J
    Acta Obstet Gynecol Scand; 2009; 88(4):463-7. PubMed ID: 19235559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer.
    Ryu KS; Kim JH; Ko HS; Kim JW; Ahn WS; Park YG; Kim SJ; Lee JM
    Gynecol Oncol; 2004 Aug; 94(2):325-32. PubMed ID: 15297169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal Chemotherapy in Patients Pretreated for Ovarian Cancer Matched with Patients Treated with Parenteral Chemotherapy.
    Nicoletto MO; Casarin A; Baldoni A; Rulli E; Tasca G; Baretta Z; Artioli G; Lombardi G; Cappetta A; Floriani I; Randon G; Valpione S; Litta P; Conte P; Mocellin S; Aliberti C
    Anticancer Res; 2016 Dec; 36(12):6541-6546. PubMed ID: 27919980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between peritoneal washing cytology through implantable port system (IPS-cytology) and second-look laparotomy in ovarian cancer patients with unmeasurable residual diseases.
    Fujiwara K; Yamauchi H; Yoshida T; Suzuki S; Oda T; Kohno I
    Gynecol Oncol; 1998 Aug; 70(2):231-5. PubMed ID: 9740696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Robella M; Vaira M; Marsanic P; Mellano A; Borsano A; Cinquegrana A; Sottile A; De Simone M
    Minerva Chir; 2014 Feb; 69(1):27-35. PubMed ID: 24675244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
    Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
    J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impacts of neoadjuvant chemotherapy and of debulking surgery on survival from advanced ovarian cancer.
    Rosen B; Laframboise S; Ferguson S; Dodge J; Bernardini M; Murphy J; Segev Y; Sun P; Narod SA
    Gynecol Oncol; 2014 Sep; 134(3):462-7. PubMed ID: 25026637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
    Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
    Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
    Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
    Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of prognostic factors after positive second-look surgery in epithelial ovarian carcinoma.
    McCreath WA; Eisenhauer EL; Abu-Rustum NR; Venkatraman ES; Caceres A; Bier R; Huh J; Cho J; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Jul; 102(1):8-14. PubMed ID: 16427689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.